YIDU TECH (02158) saw its share price surge strongly after the market opened on January 12, with gains exceeding 9% at one point. As of the time of writing, the stock was up 7.45%, trading at HK$6.35 with a turnover of HK$149 million. The positive movement follows the recent successful approval of the "Beijing Key Laboratory for Research and Transformation Application of Multimodal Intelligent Diagnosis and Treatment Systems," which was led by Peking University First Hospital and co-established with YIDU TECH's participation. This laboratory will focus on the intelligent diagnosis and treatment of cardio-renal metabolic syndrome, marking another critical milestone for YIDU TECH as it deepens its specialization in smart medical solutions. As a core co-builder of the laboratory, YIDU TECH will deeply integrate its large model technology capabilities into the lab's research and development pipeline, providing a solid foundation for the implementation of intelligent diagnosis and treatment. The global AI healthcare market is entering a phase of trillion-level growth. According to a report from Grand View Research, the global AI in healthcare market size was approximately $26.65 billion in 2024 and is projected to surge to around $505.59 billion by 2033, representing a compound annual growth rate of 38.8% during the period. Dongguan Securities indicated that as domestic tech giants actively deploy resources in the AI healthcare sector, this is expected to rapidly advance the process of medical informatization and universal access in China, accelerate the implementation of vertical AI application scenarios, with healthcare potentially becoming a significant breakthrough area for such specialized AI applications.
Comments